Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of myeloid neoplasms in Spain (2002-2013), a population-based study of the Spanish network of cancer registries

  • Solans, Marta|||0000-0002-2397-0435
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Ameijide, Alberto
  • Merino, Susana
  • Rojas, Dolores
  • Alemán, Araceli
  • Banqueri, Emilia
  • Chico, Matilde
  • Marcos, Ana Isabel
  • de Castro, Visitación
  • Gil, Leire
  • López de Munain, Arantza|||0000-0001-6820-9124
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Perucha, Josefina
  • Ruiz-Armengol, Patricia
  • Chirlaque López, María Dolores
  • Guevara, Marcela|||0000-0001-9242-6364
  • Carulla, Marià
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002-2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASR), incidence trends, and estimates for 2021 were calculated. ASR per 100,000 inhabitants was 5.14 (95% CI: 5.00-5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59-4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79-4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78-0.88) for MDS/MPN, 0.35 (95% CI: 0.32-0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53-0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comorbidities at diagnosis, survival, and cause of death in patients with chronic lymphocytic leukemia, A population-based study

  • Villavicencio, Alicia
  • Solans, Marta|||0000-0002-2397-0435
  • Zacarías-Pons, Lluís|||0000-0001-7968-0819
  • Vidal, Anna
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Roncero, Josep Maria|||0000-0002-2447-0758
  • Saez, Marc|||0000-0003-1882-0157
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
This study aimed to examine the prevalence of comorbidities in patients diagnosed with chronic lymphocytic leukemia (CLL), and to assess its influence on survival and cause-specific mortality at a population-based level. Incident CLL cases diagnosed in the Girona province (Spain) during 2008-2016 were extracted from the Girona Cancer Registry. Rai stage and presence of comorbidities at diagnosis, further categorized using the Charlson comorbidity index (CCI), were obtained from clinical records. Observed (OS) and relative survival (RS) were estimated and Cox's proportional hazard models were used to explore the impact of comorbidity on mortality. Among the 400 cases included in the study, 380 (99.5%) presented at least one comorbidity at CLL diagnosis, with diabetes without end organ damage (21%) being the most common disease. 5-year OS and RS were 68.8 (95% CI: 64.4-73.6) and 99.5 (95% CI 3.13-106.0), respectively, which decreased markedly with increasing CCI, particularly in patients with CCI ≥ 3. Multivariate analysis identified no statistically significant association between the CCI and overall CLL-related or CLL-unrelated mortality. In conclusion, a high CCI score negatively influenced the OS and RS of CLL patients, yet its effect on mortality was statistically non-significant when also considering age and the Rai stage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

  • Solans, Marta|||0000-0002-2397-0435
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Romaguera, Dora|||0000-0002-5762-8558
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gracia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • González Barca, Eva|||0000-0002-1323-1508
  • Banda, Esmeralda de la
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias|||0000-0001-9850-9793
  • Llorca, Javier|||0000-0001-8569-861X
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • Gimeno, Eva|||0000-0002-3534-6189
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Sanjose, Sílvia de
  • Amiano, Pilar
  • Casabonne, Delphine
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.